Farxiga's Impressive Growth & Performance in 2025 Farxiga, AstraZenecas flagship therapy within the Cardiovascular, Renal & Metabolism (CVRM) segment, continues to shine as one of the companys strongest growth drivers
Insurance companies may cover tirzepatide for type 2 diabetes or any other weight-related condition, but not for weight loss alone
Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
With just one injection a week, its designed to fit effortlessly into your life, so you can focus on feeling your best and achieving your health journey with confidence
Acute emotional symptoms (irritability, sadness, anxiety) increased time to recovery by 5.5%
Certain chips, cold-cut meats, and pre-packaged snacks often contain high amounts of unhealthy (trans and saturated) fats, sugars, and sodium